Results
1
-
1
of
1
A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease
,
Respiratory Research
[DOI: 10.1186/s12931-017-0647-1]